Wednesday, July 8, 2026

Patent intelligence · US

US 9981092

Pressurised metered dose inhalers and method of manufacture

granted A61KA61K9/0073A61K9/008A61K9/2009
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 12
Applicant portfolio 69
Patent details — US 9981092
Jurisdiction
US
Status
granted
Grant date
May 29, 2018
Expiration
May 24, 2038
Claims
27
CPC classes
A61K, A61K9/0073, A61K9/008, A61K9/2009
View on Google Patents ↗

Quick answer

US 9981092 (Pressurised metered dose inhalers and method of manufacture) is held by Cardiff Scintigraphics Limited. Status: granted. Granted May 29, 2018. Expires May 24, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
27
CPC classes
A61K, A61K9/0073, A61K9/008, A61K9/2009, A61K9/2013, A61K9/2018

More from Cardiff Scintigraphics Limited

Related pharmaceutical patents in our USPTO index.

  1. US 12383540

    Compounds that modulates AMPA receptor function

    University College Cardiff Consultants Limited · Expires Aug 7, 2045

    granted
  2. US 12318418

    Modified adenoviruses

    University College Cardiff Consultants Limited · Expires May 29, 2045

    granted
  3. US 12263173

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Expires Mar 27, 2045

    granted
  4. US 12144813

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Expires Nov 14, 2044

    granted
  5. US 12053513

    Cancer-specific T-cell receptors

    University College Cardiff Consultants Limited · Expires Aug 1, 2044

    granted
  6. US 11957677

    Cancer treatment using FGFR inhibitors and PLK1 inhibitors

    Cardiff Oncology, Inc. · Expires Apr 11, 2044

    granted
  7. US 11850264

    Gamma delta T-cell receptor and its ligand

    University College Cardiff Consultants Limited · Expires Dec 21, 2043

    granted
  8. US 11725039

    α/β t-cell receptor and methods of using it

    University College Cardiff Consultants Limited · Expires Aug 10, 2043

    granted

Frequently asked questions

What is US patent 9981092?

US 9981092 (Pressurised metered dose inhalers and method of manufacture) is held by Cardiff Scintigraphics Limited. Status: granted. Granted May 29, 2018. Expires May 24, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9981092?

Cardiff Scintigraphics Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.

When does US 9981092 expire?

Our index shows an expiration date of May 24, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.